TABLE 2.
The patterns of early TACE refractoriness in patients with HCC.
| Characteristics | Total (n = 204) | Training cohort (n = 147) | Validation cohort (n = 57) | p Value |
|---|---|---|---|---|
| Viable lesions >50%, n (%) | 47 (23.0%) | 28 (19.0%) | 19 (33.3%) | 0.093 |
| Presence of new lesions, n (%) | 7 (3.4%) | 4 (2.7%) | 3 (5.3%) | 0.390 |
| Vascular invasion, n (%) | 9 (4.4%) | 4 (2.7%) | 5 (8.8%) | 0.074 |
| Extrahepatic spread, n (%) | 5 (2.5%) | 5 (3.4%) | 0 (0.0) | - |
| Elevation of AFP, n (%) | 31 (15.2%) | 24 (16.3%) | 7 (12.3%) | 0.532 |
Note: TACE, transarterial chemoembolization; HCC, hepatocellularcarcinoma; AFP, alpha-fetoprotein.